Enterprise Value
45.63M
Cash
141.5M
Avg Qtr Burn
-23.99M
Short % of Float
1.66%
Insider Ownership
3.65%
Institutional Own.
67.09%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ixoberogene soroparvovec (Ixo-vec) (ADVM-022) (AAV.7m8-aflibercept) Details Wet age-related macular degeneration , Age-related macular degeneration, Eye disease | Phase 2 Data readout | |
ADVM-022 (AAV.7m8 Afiblercept) Details Diabetes, Eye disease , Diabetic macular edema | Failed Discontinued |